- Home
- TKO vs INSM Comparison
TKO vs INSM Comparison
Compare TKO & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKO
- INSM
- Stock Information
- Founded
- TKO 1980
- INSM 1988
- Country
- TKO United States
- INSM United States
- Employees
- TKO N/A
- INSM N/A
- Industry
- TKO
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- TKO
- INSM Health Care
- Exchange
- TKO Nasdaq
- INSM Nasdaq
- Market Cap
- TKO 13.1B
- INSM 14.3B
- IPO Year
- TKO N/A
- INSM 2000
- Fundamental
- Price
- TKO $153.04
- INSM $72.00
- Analyst Decision
- TKO Strong Buy
- INSM Strong Buy
- Analyst Count
- TKO 15
- INSM 16
- Target Price
- TKO $153.21
- INSM $95.36
- AVG Volume (30 Days)
- TKO 2.6M
- INSM 1.5M
- Earning Date
- TKO 05-07-2025
- INSM 05-08-2025
- Dividend Yield
- TKO 0.99%
- INSM N/A
- EPS Growth
- TKO N/A
- INSM N/A
- EPS
- TKO 0.02
- INSM N/A
- Revenue
- TKO $2,804,341,000.00
- INSM $363,707,000.00
- Revenue This Year
- TKO $19.21
- INSM $30.31
- Revenue Next Year
- TKO $22.52
- INSM $118.39
- P/E Ratio
- TKO $9,408.40
- INSM N/A
- Revenue Growth
- TKO 67.43
- INSM 19.17
- 52 Week Low
- TKO $85.01
- INSM $21.92
- 52 Week High
- TKO $179.09
- INSM $84.91
- Technical
- Relative Strength Index (RSI)
- TKO 52.62
- INSM 36.27
- Support Level
- TKO $146.69
- INSM $76.05
- Resistance Level
- TKO $158.00
- INSM $79.12
- Average True Range (ATR)
- TKO 5.11
- INSM 2.62
- MACD
- TKO 0.92
- INSM -0.37
- Stochastic Oscillator
- TKO 75.13
- INSM 0.63
About TKO TKO Group Holdings Inc.
TKO Group Holdings Inc is a premium sports and entertainment company that comprises UFC, the world's mixed martial arts organization, and WWE, an integrated media organization and the recognized leader in sports entertainment.
About INSM Insmed Incorporated
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.